CN Patent

CN109232541B — 脯氨酰羟化酶与组蛋白去乙酰化酶双重抑制剂及其制备方法和应用

Assigned to Institute of Radiation Medicine of CAMMS · Expires 2020-04-24 · 6y expired

What this patent protects

本发明公开了一种式Ⅰ所示新的脯氨酰羟化酶与组蛋白去乙酰化酶双重抑制剂及其制备方法和应用，通过同时抑制脯氨酰羟化酶(PHD)和组蛋白去乙酰化酶(HDAC)的活性，起到选择性提高乏氧诱导因子‑2α(HIF‑2α)水平，有望成为新的辐射防护药物。

USPTO Abstract

本发明公开了一种式Ⅰ所示新的脯氨酰羟化酶与组蛋白去乙酰化酶双重抑制剂及其制备方法和应用，通过同时抑制脯氨酰羟化酶(PHD)和组蛋白去乙酰化酶(HDAC)的活性，起到选择性提高乏氧诱导因子‑2α(HIF‑2α)水平，有望成为新的辐射防护药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN109232541B
Jurisdiction
CN
Classification
—
Expires
2020-04-24
Drug substance claim
No
Drug product claim
No
Assignee
Institute of Radiation Medicine of CAMMS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.